Recent success of second generation drugs targeting androgen receptor axis including enzalutamide and abiraterone acetate, which blocks intratumoral production of androgen, have been approved by the Food and Drug Administration for the treatment of castration-sensitive and castration-resistant prostate cancer patients [3,4,5,6]. This evidence concerns the gene AR and prostate cancer.